Integrated multi-omic delineation of SARS-CoV-2-dysregulated cellular processes
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:2 publications
Grant number: 172641
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$592,621.5Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
CanadaLead Research Institution
University of Manitoba Medical Microbiology and Infectious DiseasesResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
As of May 10 2020, there were a reported >4 million confirmed cases and > 285,000 deaths attributed to the novel coronavirus (CoV) SARS-CoV-2, causing the COVID-19 disease. Our understanding of the molecular factors that are responsible for the virulence and the selection of host cells to be infected by SARS-CoV-2 that could explain the emerging variety of clinical symptoms reported in COVID-19 patients is rudimentary at best. All strategies of rapidly developing tools to mitigate this catastrophic SARS-CoV-2 pandemic are fundamentally dependent on us identifying and controlling those proteins that execute the cellular mechanisms critical for SARS-CoV-2 virus to infect and replicate in host cells. We will use a powerful novel tool, called SOMAscan, to rapidly determine how COVID-19 (SARS-CoV-2 coronavirus), and a variety of other coronaviruses, affect large numbers of proteins in different human lung cells, the normal target of the COVID-19 virus. By examining how non-pathogenic, and highly pathogenic, coronaviruses, such as SARS-1, MERS and SARS-CoV-2 specifically and differentially affect cellular proteins, we will learn the unique ways in which the deadly coronaviruses can cause disease. We also will examine how these cellular proteins, and virus infection, are influenced by treatment with a variety of anti-viral agents, some of which are currently in clinical trials, to improve the information gained in these complementary clinical trials. Finally, we also will determine how affecting some of the proteins we identify can impact coronavirus-mediated growth and disease processes. Results obtained in this research will provide vital fundamental information about the molecular replication of the SARS-CoV-2 virus and will form the foundation for more in-depth studies, all of which will pave the way for more effective therapeutic interventions to improve human health.
Publicationslinked via Europe PMC
Last Updated:a day ago
View all publications at Europe PMC